Investment Thesis — Natera, Inc.
The market underestimates Natera's ability to expand its genetic testing platform beyond prenatal into oncology, where reimbursement and adoption curves are steeper. Investors are anchored to legacy growth rates, missing the inflection point as payers increasingly cover advanced diagnostics.
Catalysts
- Positive payer reimbursement decisions for oncology diagnostics
- Regulatory approval of new multi-indication tests
- Clinical trial data demonstrating superior outcomes
Risk Factors
- Payer reimbursement delays or denials
- Regulatory setbacks for oncology products
- Competitive displacement by faster-moving diagnostics firms
Key Debates
Net Margin turns positive by H1 2025 from operating leverage
53.9% revenue growth sustains through H1 2025
63.7% Gross Margin expands to 65% by H1 2025